Contract Research

From Office of Health Economics
Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).

Access Statistics for this working paper series.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

002236: Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions

Nadine Henderson;Maria Errea;Chris Skedgel;Mireia Jofre-Bonet

002201: Data Governance Arrangements for Real-World Evidence in Japan

Hideo Yasunaga;Hayato Yamana;Adrian Towse

002197: Unrelieved Pain in Palliative Care in England

Bernarda Zamora;Graham Cookson;Martina Garau

002108: Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

Nancy Devlin;Koonal Shah;Grace Hampson

002096: Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

Amanda Cole;Adrian Towse

002051: Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

Phill O’Neill;Adrian Towse;Jimena Ferraro

002047: The Impact of New Medicines in the NHS: 70 Years of Innovation

Christopher Sampson

002023: Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

Koonal Shah;Mike Herdman;Yvonne Summers;Nancy Devlin;Patricia Cubi-Molla

002015: A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”

Karla Hernandez - Villafuerte;Brendan Shaw;Adrian Towse

002009: The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

Adrian Towse;Amanda Cole;Bernarda Zamora

001978: Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Adrian Towse;Martina Garau

001976: Barriers to Uptake of Minimal Access Surgery in the United Kingdom

Christopher Sampson

001944: Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”

Mikel Berdud;Adrian Towse;Jorge Mestre-Ferrandiz

001932: Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure

Bernarda Zamora;Francois Maignen;Paula Lorgelly

001910: Data Governance Arrangements for Real-World Evidence: South Korea

Amanda Cole;Eui-Kyung Lee;Jae-A Park;Jorge Mestre-Ferrandiz

001818: Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Bernarda Zamora;Phill O’Neill;Martina Garau;Francois Maignen;Jorge Mestre-Ferrandiz

001802: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

Grace Hampson;Adrian Towse

001743: Four Case Studies to Explore the Added Value of Oxford AHSN

Grace Hampson;Bernarda Zamora;Adrian Towse;Adam Martin;Jo Exley

001699: Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making

Patricia Cubi-Molla;Adrian Towse;Sarah Karlsberg-Schaffer;Nancy Devlin

001688: Assessing Trends in SMC Advice Decisions (October 2009- September 2015)

Phill O’Neill;Bernarda Zamora

001660: Data Governance Arrangements for Real-World Evidence

Amanda Cole;Adrian Towse;Lou Garrison;Jorge Mestre-Ferrandiz

001645: Estimation of Future Cases of Dementia from Those Born in 2015

Fraser Lewis

001595: Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK

Amanda Cole

001576: Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices?

Koonal Shah;Nancy Devlin;Paul Barnsley;Amanda Cole

001504: Obstructive Sleep Apnoea: Health Economics Report

Juan Carlos Rejon-Parilla;Martina Garau

000518: The Trajectory of Dementia in the UK - Making a Difference

Fraser Lewis;Lesley Cockcroft;Phill O’Neill

000265: Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions

Alastair Gray;Paul Fenn;Clive Pritchard;Ed Godber;Martina Garau;Adrian Towse

000236: Medical Research: What's It Worth?

Office of Health Economics

000234: Assessment and Appraisal of Oncology Medicines: NICE's Approach and International HTA Experience

Koonal Shah;Qing Wang;Michael F. Drummond;Anne R. Mason;Martina Garau;Adrian Towse

000229: Forward Together: Complementarity of Public and Charitable Research with Respect to Private Research Spending

Jorge Mestre-Ferrandiz;Jon Sussex

000212: Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe

Jorge Mestre-Ferrandiz;Ruth Puig-Peiro;Adrian Towse

000210: The Publicly Funded Vaccines Market in the UK

Jon Sussex;Koonal Shah

000206: The Publicly Funded Vaccines Market in Australia

Jon Sussex;Koonal Shah;Jim Butler

000203: Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society

Jorge Mestre-Ferrandiz;Jon Sussex;Martina Garau;Phill O’Neill

000192: The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response

Nancy Devlin;Emma Hawe;Lou Garrison;Adrian Towse

000187: Exploring the Interdependency between Public and Charitable Medical Research

Arik Mordoh;Martina Garau

000169: Time Trends in NICE HTA Decisions

Nancy Devlin;Ruth Puig-Peiro;Phill O’Neill

000144: International Comparisons of Medicines Prices: 2011 Indices

Ruth Puig-Peiro;Jorge Mestre-Ferrandiz;Jon Sussex;Phill O’Neill

000050: The Expanding Value Footprint of Oncology Treatments

Juan Carlos Rejon-Parilla;Karla Hernandez-Villafuerte;Koonal Shah;Jorge Mestre-Ferrandiz;Lou Garrison;Adrian Towse

000001: Health and the Use of Medicines in Primary Care in Wales

Lesley Cockcroft;Emma Hawe;Rick Greville;Phill O’Neill